$MCRB
Seres Therapeutics, Inc.

2021 Q4 Form 10-K Financial Statement

#000095017022002435 Filed on March 01, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $7.221M $144.9M $17.56M
YoY Change -58.88% 336.33% 130.45%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $20.51M $69.26M $10.60M
YoY Change 93.45% 125.02% 83.39%
% of Gross Profit
Research & Development $36.75M $141.9M $24.87M
YoY Change 47.78% 56.66% 18.26%
% of Gross Profit
Depreciation & Amortization $1.552M $5.947M $1.500M
YoY Change 3.47% -9.59% -16.67%
% of Gross Profit
Operating Expenses $56.65M $209.4M $35.46M
YoY Change 59.77% 72.58% 32.24%
Operating Profit -$64.49M
YoY Change -26.82%
Interest Expense -$253.0K -$40.00K -$150.0K
YoY Change 68.67% -97.98% -28.57%
% of Operating Profit
Other Income/Expense, Net -$316.0K -$1.085M -$210.0K
YoY Change 50.48% 8.83% -133.33%
Pretax Income -$50.00M -$65.58M -$18.25M
YoY Change 173.98% -26.42% -2.82%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$50.00M -$65.58M -$18.25M
YoY Change 173.98% -26.42% -2.81%
Net Earnings / Revenue -692.44% -45.25% -103.93%
Basic Earnings Per Share -$0.72
Diluted Earnings Per Share -$544.3K -$715.1K -$199.6K
COMMON SHARES
Basic Shares Outstanding 91.85M 91.70M
Diluted Shares Outstanding 91.70M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $290.7M $290.7M $253.6M
YoY Change 14.63% 14.63% 167.47%
Cash & Equivalents $180.0M $180.0M $116.0M
Short-Term Investments $110.7M $110.7M $137.6M
Other Short-Term Assets $12.92M $12.92M $5.800M
YoY Change 122.79% 122.79% 61.11%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $9.387M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $303.6M $303.6M $268.8M
YoY Change 12.97% 12.96% 168.27%
LONG-TERM ASSETS
Property, Plant & Equipment $17.94M $36.15M $13.90M
YoY Change 29.08% 57.84% -28.72%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $495.0K $495.0K $49.80M
YoY Change -99.01% -99.01%
Other Assets $5.189M $14.59M $1.400M
YoY Change 270.64% 942.14% 0.0%
Total Long-Term Assets $51.23M $51.23M $74.16M
YoY Change -30.92% -30.86% 129.96%
TOTAL ASSETS
Total Short-Term Assets $303.6M $303.6M $268.8M
Total Long-Term Assets $51.23M $51.23M $74.16M
Total Assets $354.9M $354.9M $342.9M
YoY Change 3.48% 3.49% 158.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.74M $13.74M $4.018M
YoY Change 241.84% 243.38% -17.31%
Accrued Expenses $15.83M $15.83M $11.80M
YoY Change 34.12% 34.12% 29.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $500.0K
YoY Change -100.0% -100.0%
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $82.26M $82.26M $46.42M
YoY Change 77.22% 77.28% 0.92%
LONG-TERM LIABILITIES
Long-Term Debt $24.64M $24.64M $24.60M
YoY Change 0.17% 0.17% 0.0%
Other Long-Term Liabilities $11.50M $116.5M $1.003M
YoY Change 1046.06% 19.93% 99.8%
Total Long-Term Liabilities $11.50M $141.1M $1.003M
YoY Change 1046.06% 15.94% 99.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $82.26M $82.26M $46.42M
Total Long-Term Liabilities $11.50M $141.1M $1.003M
Total Liabilities $223.4M $223.4M $168.2M
YoY Change 32.8% 32.79% -6.96%
SHAREHOLDERS EQUITY
Retained Earnings -$614.4M -$548.8M
YoY Change 11.95% 19.39%
Common Stock $745.9M $723.6M
YoY Change 3.09% 75.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $131.5M $131.5M $174.8M
YoY Change
Total Liabilities & Shareholders Equity $354.9M $354.9M $342.9M
YoY Change 3.48% 3.49% 158.94%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$50.00M -$65.58M -$18.25M
YoY Change 173.98% -26.42% -2.81%
Depreciation, Depletion And Amortization $1.552M $5.947M $1.500M
YoY Change 3.47% -9.59% -16.67%
Cash From Operating Activities -$51.86M $6.688M -$17.90M
YoY Change 189.74% -107.14% 27.86%
INVESTING ACTIVITIES
Capital Expenditures -$1.578M $9.566M -$200.0K
YoY Change 689.0% 1518.61% 0.0%
Acquisitions
YoY Change
Other Investing Activities $14.76M $73.65M -$75.10M
YoY Change -119.66% -146.53% -1632.65%
Cash From Investing Activities $13.19M $64.09M -$75.30M
YoY Change -117.51% -140.33% -1702.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -780.0K 1.178M 2.000M
YoY Change -139.0% -99.61% -92.03%
NET CHANGE
Cash From Operating Activities -51.86M 6.688M -17.90M
Cash From Investing Activities 13.19M 64.09M -75.30M
Cash From Financing Activities -780.0K 1.178M 2.000M
Net Change In Cash -39.46M 71.95M -91.20M
YoY Change -56.74% 41.3% -677.22%
FREE CASH FLOW
Cash From Operating Activities -$51.86M $6.688M -$17.90M
Capital Expenditures -$1.578M $9.566M -$200.0K
Free Cash Flow -$50.29M -$2.878M -$17.70M
YoY Change 184.1% -96.94% 28.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001609809
CY2019 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#LicenseAndServiceMember
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-37465
CY2021 dei Entity Registrant Name
EntityRegistrantName
Seres Therapeutics, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4326290
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Sidney Street – 4th Floor
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
CY2021 dei City Area Code
CityAreaCode
617
CY2021 dei Local Phone Number
LocalPhoneNumber
945-9626
CY2021 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2021 dei Trading Symbol
TradingSymbol
MCRB
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
1645330768
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
92014368
CY2021 dei Auditor Firm
AuditorFirmId
238
CY2021 dei Auditor Name
AuditorName
PricewaterhouseCoopers LLP
CY2021 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
180002000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
116049000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
110704000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
137567000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12922000
CY2021Q4 us-gaap Liabilities
Liabilities
223352000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8000000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5774000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9387000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
303628000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
268777000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17938000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13897000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18208000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9041000
CY2021Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2020Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1400000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
495000
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
49825000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5189000
CY2021Q4 us-gaap Assets
Assets
354859000
CY2020Q4 us-gaap Assets
Assets
342940000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13735000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4018000
CY2021Q4 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
45094000
CY2020Q4 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
14226000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6610000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5115000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
454000
CY2021Q4 mcrb Contract With Customer Liability Current Related Party
ContractWithCustomerLiabilityCurrentRelatedParty
16819000
CY2020Q4 mcrb Contract With Customer Liability Current Related Party
ContractWithCustomerLiabilityCurrentRelatedParty
22602000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
82258000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
46415000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
24643000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
24639000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17958000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10561000
CY2021Q4 mcrb Contract With Customer Liability Noncurrent Related Party
ContractWithCustomerLiabilityNoncurrentRelatedParty
86998000
CY2020Q4 mcrb Contract With Customer Liability Noncurrent Related Party
ContractWithCustomerLiabilityNoncurrentRelatedParty
85572000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
11495000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1003000
CY2020Q4 us-gaap Liabilities
Liabilities
168190000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
90570000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
91889418
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
91889418
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
91459239
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
91459239
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
92000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
91000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
745829000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
723482000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-60000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-47000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-614354000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-548776000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
131507000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
174750000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
354859000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
342940000
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
21098000
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
0
CY2021Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
10585000
CY2020Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
0
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
143857000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11897000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27188000
CY2021 mcrb Revenue From Grant
RevenueFromGrant
1070000
CY2020 mcrb Revenue From Grant
RevenueFromGrant
4157000
CY2019 mcrb Revenue From Grant
RevenueFromGrant
1102000
CY2020 mcrb Revenue From Research Agreement
RevenueFromResearchAgreement
17161000
CY2019 mcrb Revenue From Research Agreement
RevenueFromResearchAgreement
6215000
CY2021 us-gaap Revenues
Revenues
144927000
CY2020 us-gaap Revenues
Revenues
33215000
CY2019 us-gaap Revenues
Revenues
34505000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
141891000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
80141000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
69261000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30775000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24748000
CY2021 mcrb Profit Loss From Research Agreement Related Party
ProfitLossFromResearchAgreementRelatedParty
1732000
CY2019 us-gaap Restructuring Charges
RestructuringCharges
1492000
CY2021 us-gaap Operating Expenses
OperatingExpenses
209420000
CY2020 us-gaap Operating Expenses
OperatingExpenses
121345000
CY2019 us-gaap Operating Expenses
OperatingExpenses
106381000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-64493000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-71876000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-88130000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-997000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-48324000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
2870000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
946000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
1033000
CY2021 us-gaap Interest Expense Debt
InterestExpenseDebt
2910000
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
2924000
CY2019 us-gaap Interest Expense Debt
InterestExpenseDebt
502000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1045000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
981000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1066000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1085000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1597000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-65578000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-89127000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-70279000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.12
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.24
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
91702866
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
79789220
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
56649220
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-12000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-47000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-13000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-47000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-65591000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-89174000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-70279000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-48045000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
60527000
CY2019 mcrb Stock Issued During Period Value At Market Equity Offerings
StockIssuedDuringPeriodValueAtMarketEquityOfferings
512000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
145000
CY2019 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
176000
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
296000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8344000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-70279000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
243748000
CY2020 mcrb Stock Issued During Period To Related Party Value
StockIssuedDuringPeriodToRelatedPartyValue
19900000
CY2020 mcrb Stock Issued During Period Value At Market Equity Offerings
StockIssuedDuringPeriodValueAtMarketEquityOfferings
24773000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14421000
CY2020 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
120000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
462000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8824000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-47000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-89127000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
174750000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1299000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
827000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20222000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-13000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-65578000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
131507000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-65578000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-89127000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-70279000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
20222000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
8824000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
8344000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5947000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6578000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7603000
CY2021 mcrb Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
3275000
CY2020 mcrb Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
2315000
CY2019 mcrb Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
2227000
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
498000
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
446000
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
281000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2526000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-551000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
172000
CY2019 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-103000
CY2021 mcrb Profit Loss From Research Agreement Related Party
ProfitLossFromResearchAgreementRelatedParty
1732000
CY2021 mcrb Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets
-12337000
CY2020 mcrb Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets
-2186000
CY2019 mcrb Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets
3257000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-9387000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7602000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1785000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4357000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-11565000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-17520000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
9362000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1159000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1460000
CY2021 mcrb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3550000
CY2020 mcrb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-4456000
CY2019 mcrb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-4211000
CY2021 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
95971000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
145000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
43025000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3771000
CY2019 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2908000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6688000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-93610000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-76520000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9566000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
591000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1002000
CY2020 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
218284000
CY2019 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
46420000
CY2021 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
169625000
CY2020 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
59984000
CY2019 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
16904000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
64088000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-158891000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-30518000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
243748000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
60527000
CY2020 mcrb Proceeds From Securities Purchase Agreement Net Of Issuance Costs Related Party
ProceedsFromSecuritiesPurchaseAgreementNetOfIssuanceCostsRelatedParty
19900000
CY2019 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
25000000
CY2020 mcrb Proceeds From At The Market Equity Offering Net Of Commissions
ProceedsFromAtTheMarketEquityOfferingNetOfCommissions
24773000
CY2019 mcrb Proceeds From At The Market Equity Offering Net Of Commissions
ProceedsFromAtTheMarketEquityOfferingNetOfCommissions
512000
CY2019 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
425000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1299000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
14421000
CY2020 mcrb Proceeds From Issuance Of Common Stock And Restricted Common Stock
ProceedsFromIssuanceOfCommonStockAndRestrictedCommonStock
120000
CY2019 mcrb Proceeds From Issuance Of Common Stock And Restricted Common Stock
ProceedsFromIssuanceOfCommonStockAndRestrictedCommonStock
176000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
827000
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
462000
CY2019 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
296000
CY2021 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
948000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1178000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
303424000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
86231000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
71954000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
50923000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-20807000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-1000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
116049000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65126000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85933000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
188002000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
116049000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65126000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
2446000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
2453000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-614354000
CY2021Q4 mcrb Cash Cash Equivalents And Short And Long Term Investments
CashCashEquivalentsAndShortAndLongTermInvestments
291201000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-65578000
CY2021Q4 mcrb Cash Cash Equivalents And Short And Long Term Investments
CashCashEquivalentsAndShortAndLongTermInvestments
291201000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition and the accrual of research and development expenses. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenue, operating expenses, clinical trials and employee-related amounts, will depend on future developments that are highly uncertain, including new information that may emerge concerning COVID-19 and the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results could differ from the Company’s estimates.</span></p>
CY2019 us-gaap Interest Paid Net
InterestPaidNet
221000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
874000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
451000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
62000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
12442000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
154000
CY2021 mcrb Accrued Expenses And Other Current And Long Term Liabilities Related Party Amounts
AccruedExpensesAndOtherCurrentAndLongTermLiabilitiesRelatedPartyAmounts
31683000
CY2020 mcrb Accrued Expenses And Other Current And Long Term Liabilities Related Party Amounts
AccruedExpensesAndOtherCurrentAndLongTermLiabilitiesRelatedPartyAmounts
0
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 mcrb Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2010-10
CY2021 mcrb Cash Equivalents Original Maturity Maximum Period
CashEquivalentsOriginalMaturityMaximumPeriod
P90D
CY2021Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
188002000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
116049000
CY2020Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1400000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8000000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
180002000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
116049000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8000000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Concentration of Credit Risk and of Significant Suppliers</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and investments. The Company has all cash, cash equivalents and investments balances at accredited financial institutions, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is dependent on third-party manufacturers to supply products for research and development activities of its programs, including preclinical and clinical testing. These programs could be adversely affected by a significant interruption in the supply of such drug substance products.</span></p>
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q4 us-gaap Billed Contract Receivables
BilledContractReceivables
0
CY2020Q4 us-gaap Billed Contract Receivables
BilledContractReceivables
1186000
CY2021Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
0
CY2020Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
8201000
CY2021 mcrb Revenue Recognized Related To Sales Based Royalties
RevenueRecognizedRelatedToSalesBasedRoyalties
0
CY2021 mcrb Minimum Percentage Of Likelihood Of Tax Benefit Being Realized Upon Settlement
MinimumPercentageOfLikelihoodOfTaxBenefitBeingRealizedUponSettlement
0.50
CY2021Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2020Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1400000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
111258000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
59000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
111199000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
187439000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
61000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
187392000
CY2021 mcrb Cash Equivalents Original Maturity Maximum Period
CashEquivalentsOriginalMaturityMaximumPeriod
P90D
CY2020Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1400000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
110762000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
110704000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
496000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
495000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
111258000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
111199000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
137588000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
137567000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17938000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13897000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5947000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6578000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7603000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
49851000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
49825000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
187439000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
187392000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
58206000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
48217000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
40268000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
34320000
CY2021Q4 mcrb Accrued Development And Clinical Manufacturing Costs Current
AccruedDevelopmentAndClinicalManufacturingCostsCurrent
11147000
CY2020Q4 mcrb Accrued Development And Clinical Manufacturing Costs Current
AccruedDevelopmentAndClinicalManufacturingCostsCurrent
6339000
CY2021 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
Certain leases include one or more options to renew, exercised at the Company’s sole discretion, with renewal terms that can extend the lease from one year to five years.
CY2021 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
3300000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9216000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6734000
CY2021Q4 mcrb Accrued Liability Related To2021 License Agreement Current
AccruedLiabilityRelatedTo2021LicenseAgreementCurrent
21098000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3633000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1153000
CY2021Q4 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
45094000
CY2020Q4 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
14226000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18208000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9041000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6610000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5115000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17958000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10561000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
24568000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
15676000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
5170000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
4163000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
4532000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1452000
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1457000
CY2019 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1878000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
2890000
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
3022000
CY2021 us-gaap Sublease Income
SubleaseIncome
1575000
CY2020 us-gaap Sublease Income
SubleaseIncome
1813000
CY2019 us-gaap Sublease Income
SubleaseIncome
890000
CY2021 us-gaap Lease Cost
LeaseCost
8347000
CY2020 us-gaap Lease Cost
LeaseCost
6697000
CY2019 us-gaap Lease Cost
LeaseCost
8542000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
6821000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
6302000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
6514000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
8512000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7480000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2392000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2466000
CY2021Q4 mcrb Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
10891000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
31741000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7173000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
24568000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y1M13D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M20D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.11
CY2019Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.30
CY2021 us-gaap Restructuring Charges
RestructuringCharges
0
CY2020 us-gaap Restructuring Charges
RestructuringCharges
0
CY2019 us-gaap Payments For Restructuring
PaymentsForRestructuring
1299000
CY2020 us-gaap Payments For Restructuring
PaymentsForRestructuring
193000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
24051000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
24051000
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10037130
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.54
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M13D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
156627000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3603744
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
19.30
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
329112
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.84
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1794573
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.19
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11517189
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.10
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M1D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
28006768000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5590163
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.62
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y1M2D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
16670723000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.33
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.08
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20222000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8824000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8344000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
57913000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y3M29D
CY2016Q1 mcrb Collaborative Arrangement Upfront License Fee Received
CollaborativeArrangementUpfrontLicenseFeeReceived
120000000
CY2021 mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
10446000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.13
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4727000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
37255000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
244000
CY2021 mcrb Number Of Employees Granted
NumberOfEmployeesGranted
2
CY2020 mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
21565000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-65578000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-89127000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-70279000
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
91702866
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
79789220
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
56649220
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.12
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.24
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12416991
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10054416
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8530504
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.166
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.064
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.058
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2475000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1783000
CY2021Q4 mcrb Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
43000
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.028
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.078
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.068
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.004
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.058
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.017
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.004
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.002
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.007
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.404
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.408
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.360
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
108189000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
106351000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
53133000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
42311000
CY2021Q4 mcrb Deferred Tax Assets Capitalized Organization Costs
DeferredTaxAssetsCapitalizedOrganizationCosts
181000
CY2020Q4 mcrb Deferred Tax Assets Capitalized Organization Costs
DeferredTaxAssetsCapitalizedOrganizationCosts
214000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
16045000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
11615000
CY2021Q4 mcrb Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
6635000
CY2020Q4 mcrb Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
4283000
CY2021Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
50000
CY2020Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
15000
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
36666000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
29553000
CY2020Q4 mcrb Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
51000
CY2021Q4 mcrb Deferred Tax Assets Section163 J Limitation Cares Act
DeferredTaxAssetsSection163JLimitationCARESAct
1368000
CY2020Q4 mcrb Deferred Tax Assets Section163 J Limitation Cares Act
DeferredTaxAssetsSection163JLimitationCARESAct
540000
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
247000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
225032000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
196716000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
510000
CY2021Q4 mcrb Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
4918000
CY2020Q4 mcrb Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
2470000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
4918000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2980000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
220114000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
193736000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
193736000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
157346000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
132009000
CY2021 mcrb Increase In Valuation Allowance Deferred Tax Asset
IncreaseInValuationAllowanceDeferredTaxAsset
26378000
CY2020 mcrb Increase In Valuation Allowance Deferred Tax Asset
IncreaseInValuationAllowanceDeferredTaxAsset
36390000
CY2019 mcrb Increase In Valuation Allowance Deferred Tax Asset
IncreaseInValuationAllowanceDeferredTaxAsset
25337000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
220114000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
193736000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
157346000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2016Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2016Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.06
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1087000
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
586000
CY2019 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
542000

Files In Submission

Name View Source Status
0000950170-22-002435-index-headers.html Edgar Link pending
0000950170-22-002435-index.html Edgar Link pending
0000950170-22-002435.txt Edgar Link pending
0000950170-22-002435-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img112908899_0.jpg Edgar Link pending
img112908899_1.jpg Edgar Link pending
mcrb-20211231.htm Edgar Link pending
mcrb-20211231.xsd Edgar Link pending
mcrb-20211231_cal.xml Edgar Link unprocessable
mcrb-20211231_def.xml Edgar Link unprocessable
mcrb-20211231_htm.xml Edgar Link completed
mcrb-20211231_lab.xml Edgar Link unprocessable
mcrb-20211231_pre.xml Edgar Link unprocessable
mcrb-ex10_16.htm Edgar Link pending
mcrb-ex10_19.htm Edgar Link pending
mcrb-ex10_25.htm Edgar Link pending
mcrb-ex23_1.htm Edgar Link pending
mcrb-ex31_1.htm Edgar Link pending
mcrb-ex31_2.htm Edgar Link pending
mcrb-ex32_1.htm Edgar Link pending
mcrb-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending